$ALMS

Bradley Mark Christopher sold $68K of ALMS

Bradley Mark Christopher (Chief Development Officer) sold 2,572 shares of ALUMIS INC. (ALMS) at $26.37 on 2026-08-03.

Original reporting
SEC EDGAR · Bradley Mark Christopher
Published Aug 5, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 11:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMS
Neutral
low confidence
Mentioned
$ALMS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details by the named officer, including price, shares, and post-transaction holdings.

02

Market read

Traders may note insider selling, but the filing alone is usually not a standalone catalyst for repricing.

03

What to watch

The article does not provide context for the sale (taxes, scheduled liquidity needs, or prior grants), so interpreting it as a strong signal is risky.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05 after-hours; transaction dated 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for ALUMIS INC. (ALMS).

Company-level read

Ticker impact

$ALMSNeutralLow confidence
Context

ALMS disclosed an insider open-market sale by its Chief Development Officer of 2,572 shares at $26.37 on 2026-08-03.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven and typically fades unless accompanied by other company-specific news.

Evidence & confidence

The filing provides transaction size, price, and post-sale holdings, but no accompanying guidance, operational update, or enforcement/regulatory action.

Market effects

Minimal, as this is company-specific insider trading with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification; the absence of a stated 10b5-1 plan does not automatically imply bearish information.

Key entities

  • ALUMIS INC.

    Subject of the Form 4 insider transaction disclosure.

  • Bradley Mark Christopher

    Chief Development Officer who sold 2,572 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMSMed

Why is Alumis stock rallying today?

Alumis (ALMS) stock rose 6.3% in pre-market trading after presenting long-term skin-clearance data for envudeucitinib at the Cantor Fitzgerald Global Healthcare Conference. Management highlighted potential partnerships and insider Srinivas Akkaraju bought 986,000 shares. The FDA application for envudeucitinib is expected in Q4 2026.

$ALMSMedAI 8/10

Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population

Alumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus did not meet primary or secondary endpoints in the overall population. However, a prespecified subgroup with high interferon gene signature showed numerically higher responses. The company plans to discuss Phase 3 trial design with regulators. Envudeucitinib was generally well tolerated.

$ALMSMedAI 8/10

Alumis Phase 2b LUMUS Trial Misses Endpoints; Stock Plunges

Alumis Inc. (ALMS) reported Phase 2b LUMUS trial results for Envudeucitinib in SLE, missing primary and secondary endpoints overall but showing promise in a subset of patients with high interferon gene signature. The drug demonstrated improvements in several measures in this subgroup and was well tolerated. The company plans to discuss Phase 3 development with regulators. ALMS stock fell over 55% in pre-market trading.